Methyl 2-Oxoindoline-6-Carboxylate CAS 14192-26-8 Purity>99.0% (HPLC) Nintedanib Esylate Warshada Dhexe
Shanghai Ruifu Chemical Co., Ltd. waa soo saaraha iyo soo saaraha ugu horreeya ee Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) oo leh tayo sare leh, wax soo saar ganacsi.
Magaca Kiimikada | Methyl 2-Oxoindoline-6-Carboxylate |
La mid ah | 2-Oxoindoline-6-Carboxylic Acid Methyl Ester;Methyl Oxindole-6-Carboxylate |
Lambarka CAS | 14192-26-8 |
Lambarka CAT | RF-PI1524 |
Heerka Saamiyada | Kaydka dhexdiisa, Qiyaasta Waxsoosaarka Ilaa Tan |
Qaanuunka molecular | C10H9NO3 |
Miisaanka Molecular | 191.19 |
Meesha dhalaalaysa | 184.0 ~ 190.0 ℃ |
Summada | Kiimikada Ruifu |
Shayga | Tilmaamaha |
Muuqashada | Jaalle fudud ilaa budada Brown |
1 H NMR Spectrum | Waafaqsan Qaab-dhismeedka |
Daahirnimada / Habka Falanqaynta | >99.0% (HPLC) |
Khasaare xagga qalajinta | <1.00% |
Wadarta wasakhda | <1.00% |
Heerka Imtixaanka | Heerka Ganacsiga |
Isticmaalka | Dhexdhexaadiyaha Nintedanib Esylate (CAS: 656247-18-6) |
Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) Jidka synthetic
Xidhmada: Dhalo, bacda bireed ee aluminium, 25kg / Durbaan kartoonada, ama sida waafaqsan shuruudaha macmiilka.
Xaaladda Kaydinta:Ku kaydi weelasha xiran meel qabow oo qallalan;Ka ilaali iftiinka iyo qoyaanka.
Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) waa dhexdhexaad ah oo loo isticmaalo diyaarinta Nintedanib Esylate (CAS: 656247-18-6).Nintedanib Esylate waa awood xoog leh, oo afka laga qaato angiokinase inhibitor saddex-geesoodka ah oo uu sameeyay Boehringer Ingelheim kaas oo bartilmaameedsada waddooyinka proangiogenic iyo pro-fibrotic ee ay dhexdhexaadiyaan soo-dhoweeyaha xuubka korriinka endothelial, soo-dhoweeyaha koritaanka fibroblast iyo qoysaska soo-dhowaynta koritaanka platelet, iyo sidoo kale Src iyo Flt-3 kinases.Nintedanib Esylate waxaa loo ansixiyay daawaynta idiopathic pulmonary fibrosis (IPF), xaalad kaas oo sambabada ay noqdaan kuwo si tartiib tartiib ah u nabarra waqti ka dib, US FDA bishii Oktoobar 2014 iyo EMA bishii Janaayo 2015. FDA waxay siisay nintedanib esylate fast-track , dib u eegista mudnaanta leh, alaabta agoonta, iyo magacaabista horumarka.Waxa kale oo ay ansixisay EMA bishii Noofambar 2014 si loogu daweeyo kansarka sanbabada unug yar oo ay weheliso docetaxel ka dib daaweynta kiimikaad ee safka hore.